Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

被引:1164
|
作者
Stamos, J
Sliwkowski, MX
Eigenbrot, C
机构
[1] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.M207135200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-Angstrom resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva(TM)). The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains. Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor., Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain. Significant intermolecular contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.
引用
收藏
页码:46265 / 46272
页数:8
相关论文
共 50 条
  • [1] 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
    Liu, Fang
    Tang, Baoding
    Liu, Hao
    Li, Leina
    Liu, Gang
    Cheng, Yun
    Xu, Yan
    Chen, Wenwen
    Huang, Yinjiu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2016, 16 (12) : 1652 - 1664
  • [2] Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors
    Li, Si-Ning
    Xu, Yun-Yun
    Gao, Jia-Yu
    Yin, Hong-ran
    Zhang, Shi-Lei
    Li, Huan-Qiu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (13) : 3221 - 3227
  • [3] Potent 4-anilinoquinazoline inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase.
    Ghosh, S
    Liu, XP
    Narla, RK
    Jun, X
    Mao, C
    Uckun, FM
    CLINICAL CANCER RESEARCH, 1999, 5 : 3750S - 3750S
  • [4] 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase
    Lee, JY
    Park, YK
    Seo, SH
    So, IS
    Chung, HK
    Yang, BS
    Lee, SJ
    Park, H
    Lee, YS
    ARCHIV DER PHARMAZIE, 2001, 334 (11) : 357 - 360
  • [5] The combination of 4-anilinoquinazoline and cinnamic acid: A novel mode of binding to the epidermal growth factor receptor tyrosine kinase
    Li, Dong-Dong
    Lv, Peng-Cheng
    Zhang, Hui
    Zhang, Hong-Jia
    Hou, Ya-Ping
    Liu, Kai
    Ye, Yong-Hao
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (16) : 5012 - 5022
  • [6] Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases
    Baguley, BC
    Marshall, ES
    Holdaway, IM
    Rewcastle, GW
    Denny, WA
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) : 1086 - 1090
  • [7] Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity
    Xu, Yun-Yun
    Li, Si-Ning
    Yu, Gao-Jian
    Hu, Qing-Hua
    Li, Huan-Qiu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (19) : 6084 - 6091
  • [8] High performance liquid chromatography analysis of a 4-anilinoquinazoline derivative (PD153035), a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in rat plasma
    Rocco, SA
    Velho, JA
    Marin, RM
    Rolim, LD
    Vercesi, AE
    Rittner, R
    Franchini, KG
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 817 (02): : 297 - 302
  • [9] Absorption of CH330331, A Novel 4-Anilinoquinazoline Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase: Comparative Studies using In Vitro, In Situ and In Vivo Models
    Sun, Haiyan
    Bi, Huichang
    Huang, Min
    Liu, Dong
    Qin, Zhenyu
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2010, 31 (8-9) : 486 - 494
  • [10] 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
    Assefa, H
    Kamath, S
    Buolamwini, JK
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2003, 17 (08) : 475 - 493